Description

Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue, causing increased susceptibility to fractures and chronic bone pain. The main therapies for the treatment of osteoporosis are hormone replacement therapy (HRT), bisphosphonates and selective oestrogen receptor modulators (SERMs). A key driver for the market is the lack of effective drugs that have a good safety and side effect profile. With a few drugs expected to enter the market over the forecast period, competition is expected to intensify. Stratification of the market should happen, so that companies should be able to serve niche markets. The current leader however, is expected to remain the dominant provider of osteoporosis medications.